First Eagle Small Cap Opportunity Fund Q1 2026 Portfolio Review

Leading contributors in the First Eagle Small Cap Opportunity Fund this quarter included Ultra Clean Holdings, Oil States International, Lincoln Educational Services, Advanced Energy and FormFactor. Oil States International shares rallied on very strong bookings during the quarter and improved operator-powered solutions and services inside the wellbore. The leading detractors in the quarter were Vital Farms, Alphatec Holdings, Beta Bionics, SI-BONE. and Herc Holdings.

Seeking Alpha • May 6, 2026

SI-BONE To Present at BofA Securities 2026 Healthcare Conference on May 12, 2026

SANTA CLARA, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), the global leader in developing procedural solutions to address clinical challenges associated with compromised bone, today announced that the company will be participating in the upcoming 2026 BofA Securities Healthcare Conference in Las Vegas, NV. Management will be hosting a fireside chat on Tuesday, May 12, 2026, at 8:00 a.m. Pacific Time/11:00 a.m. Eastern Time.

GlobeNewsWire • Apr 30, 2026

SI-BONE To Report First-Quarter 2026 Financial Results on May 11, 2026

SANTA CLARA, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), the global leader in developing procedural solutions to address clinical challenges associated with compromised bone, today announced it will report financial results for the first quarter of 2026 after market close on Monday, May 11, 2026. Management will host a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time

GlobeNewsWire • Apr 20, 2026

SI-BONE, Inc. (SIBN) Q4 2025 Earnings Call Transcript

SI-BONE, Inc. (SIBN) Q4 2025 Earnings Call Transcript

Seeking Alpha • Feb 24, 2026

SI-BONE, Inc. Reports Record Financial Results for the Fourth Quarter 2025 and Issues 2026 Guidance

Achieves 20% worldwide revenue growth and positive adjusted EBITDA for Fiscal Year 2025Generates free cash flow in the Fourth Quarter 2025

GlobeNewsWire • Feb 23, 2026

Si-Bone (SIBN) Reports Q4 Loss, Tops Revenue Estimates

Si-Bone (SIBN) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to a loss of $0.11 per share a year ago.

Zacks Investment Research • Feb 24, 2026

SI-BONE To Present at TD Cowen 46th Annual Health Care Conference on March 2, 2026

SANTA CLARA, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), the global leader in developing procedural solutions to address clinical challenges associated with compromised bone, today announced that the company will be participating in the upcoming TD Cowen 46th Annual Health Care Conference in Boston, MA. Management will be hosting a fireside chat on Monday, March 2, 2026, at 7:30 a.m. Pacific Time/ 10:30 a.m. Eastern Time.

GlobeNewsWire • Feb 17, 2026

Earnings Preview: Si-Bone (SIBN) Q4 Earnings Expected to Decline

Si-Bone (SIBN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research • Feb 16, 2026

SI-BONE To Report Fourth-Quarter and Full-Year 2025 Financial Results on February 23, 2026

SANTA CLARA, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), the global leader in developing procedural solutions to address clinical challenges associated with compromised bone, today announced it will report financial results for the fourth quarter and full year ended December 31, 2025 after market close on Monday, February 23, 2026.

GlobeNewsWire • Feb 2, 2026

SI-BONE Announces Preliminary Revenue for the Fourth Quarter and Full Year 2025

Fiscal Year 2025 worldwide revenue of $200.8 to $200.9 million, representing growth of ~20% Fiscal Year 2025 worldwide revenue of $200.8 to $200.9 million, representing growth of ~20%

GlobeNewsWire • Jan 12, 2026